Feedback / Questions
Fablyn (lasofoxifene) - Sermonix
https://www.globenewswire.com/news-release/2024/08/27/2936274/0/en/Sermonix-Pharmaceuticals-Completes-Enrollment-of-Phase-2-I-SPY-2-Arm-Evaluating-Lasofoxifene-in-Neoadjuvant-Breast-Cancer-Setting.html
Aug 27, 2024
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Prev
Next